Clinical Trial Update: Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

A Phase 3 trial in stable kidney transplant recipients compared enteric-coated mycophenolate sodium with reduced-dose tacrolimus to EC-MPS with standard-dose ta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Enteric-coated Mycophenolate Sodium (EC-MPS) (mycophenolate sodium)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Novartis | Conditions: Kidney Diseases | Phase 3 | Status: COMPLETED | Results posted: 2011-05-02